Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Shytaj, Iart Luca ^a   Chirullo, Barbara ^a   Wagner, Wendeline ^b   Ferrari, Maria G ^c   Sgarbanti, Rossella ^d   Corte, Alessandro Della ^a   LaBranche, Celia ^e   Lopalco, Lucia ^f   Palamara, Anna Teresa ^g,h   Montefiori, David ^e   Lewis, Mark G ^b   Garaci, Enrico ^a   Savarino, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b BIOQUAL INC   (United States)

^c ABL Associates Inc   (United States)

^d SECTION OF MATHEMATICS   (Italy)

^e DUKE UNIVERSITY   (United States)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Antireservoir therapy; Auranofin; Buthionine sulfoximine; Eradication research; Functional cure of HIV AIDS; Macaque AIDS model; SIVmac251 infection; Viral reservoirs

Indexed keywords

AURANOFIN; BUTHIONINE SULFOXIMINE; DARUNAVIR; EMTRICITABINE; GAMMA INTERFERON; MARAVIROC; NEUTRALIZING ANTIBODY; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; INFECTION CONTROL; NONHUMAN; REBOUND; REMISSION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AURANOFIN; BUTHIONINE SULFOXIMINE; DNA, VIRAL; IMMUNITY, CELLULAR; MACACA; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

ANIMALIA; MACACA; SIMIAE;

EID: 84880096840     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-71     Document Type: Article

References (50)

1. Lafeuillade A. Translational eradication approaches. Curr Opin HIV AIDS 2006, 1(2):141-146.
2. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329(5988):174-180.
3. Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology 2012, 9:57.
4. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
5. Pandrea I, Gaufin T, Gautam R, Kristoff J, Mandell D, Montefiori D, Keele BF, Ribeiro RM, Veazey RS, Apetrei C. Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8 + cell depletion. PLoS Pathog 2011, 7(8):e1002170.
6. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122(8):573-579.
7. de Boer RJ, Boerlijst MC. Diversity and virulence thresholds in AIDS. Proc Natl Acad Sci USA 1994, 91(2):544-548.
8. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94(24):13193-13197.
9. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009, 15(8):893-900.
10. Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology 2012, 9:82.
11. Savarino A, Garaci E. Therapeutic imprinting of the immune system: towards a remission of AIDS in primates?. Retrovirology 2012, 9:75.
12. Shytaj IL, Norelli S, Chirullo B, Della Corte A, Collins M, Yalley-Ogunro J, Greenhouse J, Iraci N, Acosta EP, Barreca ML, Lewis MG, Savarino A. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012, 8(6):e1002774.
13. Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A, Collins M, Wagner WL, Yalley-Ogunro J, Greenhouse J, Chirullo B, Norelli S, Garaci E, Savarino A. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 2011, 25(11):1347-1356.
14. Chirullo B, Sgarbanti R, Lewis MG, Boe A, Norelli S, Biffoni M, Pelosi E, Garaci E, Palamara AT, Savarino A. Modulation of Oxidative Stress Induces Apoptosis in Long-Lived Phenotypes ex vivo. In Final Program and Abstracts of the 5th International Workshop on HIV Persistence during Therapy, St Maarten, West Indies, December 6-9, 2011, oral presentation 30. Global Antiviral J 2011, 7(suppl 2):23-24.
15. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D, Altucci L, Palamara AT, Garaci E. " Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009, 6:52.
16. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997, 89(23):1789-1796.
17. Berglöf FE, Berglöf K, Walz DT. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J Rheumatol 1978, 5(1):68-74.
18. Gutiérrez C, Díaz L, Vallejo A, Hernández-Novoa B, Abad M, Madrid N, Dahl V, Rubio R, Moreno AM, Dronda F, Casado JL, Navas E, Pérez-Elías MJ, Zamora J, Palmer S, Muñoz E, Muñoz-Fernández M, Moreno S. Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1infection: effect on T cells latently infected. PLoS One 2011, 6(12):e27864.
19. Yang Y, Al-Mozaini M, Buzon MJ, Beamon J, Ferrando-Martinez S, Ruiz-Mateos E, Rosenberg ES, Pereyra F, Yu XG, Lichterfeld M. CD4 T-cell regeneration in HIV-1 elite controllers. AIDS 2012, 26(6):701-706.
20. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, Dewar R, Marovich M, van Griensven F, Sekaly R, Pinyakorn S, Phanuphak N, Trichavaroj R, Rutvisuttinunt W, Chomchey N, Paris R, Peel S, Valcour V, Maldarelli F, Chomont N, Michael N, Phanuphak P, Kim JH. RV254/SEARCH 010 Study Group Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012, 3:e33948. RV254/SEARCH 010 Study Group.
21. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010, 24(10):1598-1601.
22. Reinhart TA, Rogan MJ, Huddleston D, Rausch DM, Eiden LE, Haase AT. Simian immunodeficiency virus burden in tissues and cellular compartments during clinical latency and AIDS. J Infect Dis 1997, 176(5):1198-1208.
23. Lee EM, Chung HK, Livesay J, Suschak J, Finke L, Hudacik L, Galmin L, Bowen B, Markham P, Cristillo A, Pal R. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J Virol Methods 2010, 163(2):287-294.
24. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998, 72(1):164-169.
25. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283(5403):857-860.
26. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79(16):10108.
27. Cox AG, Brown KK, Arner ES, Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involvesperoxiredoxin 3 oxidation. Biochem Pharmacol 2008, 76(9):1097-1109.
28. Rigobello MP, Folda A, Dani B, Menabò R, Scutari G, Bindoli A. Gold(I)complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur J Pharmacol 2008, 582(1-3):26-34.
29. Griffith OW, Meister A. Potent and specific inhibition of glutathionesynthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979, 254(16):7558-7560.
30. Griffith OW. Mechanism of action, metabolism, and toxicity of buthioninesulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 1982, 257(22):13704-13712.
31. Pani G, Colavitti R, Borrello S, Galeotti T. Redox regulation of lymphocyte signaling. IUBMB Life 2000, 49(5):381-389. Review.
32. Los M, Schenk H, Hexel K, Baeuerle PA, Dröge W, Schulze-Osthoff K. IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J 1995, 14(15):3731-3740.
33. Chiang CL, Ledermann JA, Rad AN, Katz DR, Chain BM. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 2006, 55(11):1384-1395.
34. Kienast A, Preuss M, Winkler M, Dick TP. Redox regulation of peptide receptivity of major histocompatibility complex class I molecules by ERp57 and tapasin. Nat Immunol 2007, 8(8):864-872.
35. Chiang CL, Ledermann JA, Aitkens E, Benjamin E, Katz DR, Chain BM. Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 2008, 14(15):4898-4907.
36. Prokopowicz ZM, Arce F, Biedroń R, Chiang CL, Ciszek M, Katz DR, Nowakowska M, Zapotoczny S, Marcinkiewicz J, Chain BM. Hypochlorous acid: a natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity. J Immunol 2010, 184(2):824-835.
37. Klatt NR, Silvestri G, Hirsch V. Nonpathogenic simian immunodeficiency virus infections. Cold Spring Harb Perspect Med 2012, 2(1):a007153.
38. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360(7):692-698.
39. Lori F, Lewis MG, Xu J, Varga G, Zinn DE, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000, 290(5496):1591-1593.
40. Benlhassan-Chahour K, Penit C, Dioszeghy V, Vasseur F, Janvier G, Rivière Y, Dereuddre-Bosquet N, Dormont D, Le Grand R, Vaslin B. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J Virol 2003, 77(23):12479-12493.
41. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C. ANRS VISCONTI Study Group Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013, 9(3):e1003211. ANRS VISCONTI Study Group.
42. Chen HY, Di Mascio M, Perelson AS, Ho DD, Zhang L. Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci USA 2007, 104(48):19079-19084.
43. Bacchetti P, Deeks SG, McCune JM. Breaking free of sample size dogma to perform innovative translational research. Sci Transl Med 2011, 3(87):87ps24.
44. Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, Lin W, Khunkhun R, Piatak M, Lifson JD, Grosschupff G, Gelman RS, Racz P, Tenner-Racz K, Mansfield KA, Letvin NL, Montefiori DC, Reimann KA. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003, 77:2165-2173.
45. Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010, 7:21.
46. Romano JW, Shurtliff RN, Dobratz E, Gibson A, Hickman K, Markham PD, Pal R. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 2000, 86:61-70.
47. Deiman B, van Aarle P, Sillekens P. Characteristics and applications of sequence-based amplification (NASBA). Mol Biotechnol 2002, 20:163-179.
48. Diop OM, Gueye A, Dias-Tavares M, Kornfeld C, Faye A, Ave P, Huerre M, Corbet S, Barre-Sinoussi F, Müller-Trutwin MC. High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol 2000, 74(16):7538-7547.
49. Hatano H, Vogel S, Yoder C, Metcalf JA, Dewar R, Davey RT, Polis MA. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 2000, 14(10):1357-1363.
50. Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 2009, 5(10):e1000533.